Early Conversion of Prolonged-release Tacrolimus in Liver Transplantation.
Status:
Not yet recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
Tacrolimus is a commonly used immunosuppressant after liver transplantation. A once-daily
administration of prolonged-release tacrolimus has been found to improve patient compliance
and offer good efficacy and safety. Moreover, there is evidence that this prolonged-release
formulation mitigates renal impairment and metabolic syndrome in transplant recipients.
Foreign studies have confirmed that it is safe and feasible for liver transplant recipients
to switch from immediate-release tacrolimus to prolonged-release tacrolimus during the stable
period. At the same time, patients with early conversion are more likely to benefit in terms
of graft survival and renal function recovery, and the proportion of drug conversion needs to
be further explored.
This study aims to assess the efficacy and safety of switching from immediate-release
tacrolimus to prolonged-release tacrolimus three months after liver transplantation.
Furthermore, it seeks to investigate the impact of this conversion on indicators such as
liver function, kidney function, metabolic disease incidence, and infection incidence in
patients.